In generalized myasthenia gravis (gMG), the therapeutic rationale for complement C5 inhibition is grounded in a well-defined immunopathological cascade.
Products are supplied to verified businesses, institutions, and qualified professionals for research and development use only. Not for use in humans, animals, diagnosis, or therapy.
